• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Don't Underestimate Vertex Pharmaceuticals

Here's how the stock might surprise Wall Street.
By BRUCE KAMICH
Jan 31, 2020 | 12:16 PM EST
Stocks quotes in this article: VRTX

During the Lightning Round segment of Mad Money Thursday night one caller asked Jim Cramer about Vertex Pharmaceuticals Inc. (VRTX) : "Wall Street underestimates this stock," said Cramer. Let's check and see how VRTX might surprise the sell side.

In the daily bar chart of VRTX, below, we can see that the stock price turned up strongly from early October when the broad market started its fourth-quarter rally. Prices pulled back toward the rising 50-day moving average line in early January in what looks like a buying opportunity. Prices are above the rising 200-day moving average line and maybe even extended above it.

The trading volume has been stronger since the middle of October telling us that more traders and investors have been attracted to the stock. The daily On-Balance-Volume (OBV) line started its rise in early October and tells us that buyers of VRTX have been more aggressive.

The Moving Average Convergence Divergence (MACD) oscillator gave a go long signal in late October when it crossed above the zero line. Another buy signal could be seen in early February if this stock keeps rising. 

 
 
In the weekly bar chart of VRTX, below, we can see that the prices were in an uptrend back in 2017 and then went into a lengthy consolidation pattern before resuming the uptrend this past October. VRTX is above the rising 40-week moving average line.
 
After a long sideways trend the weekly OBV line has broken out to new highs to confirm the new price highs. The MACD oscillator on this longer time frame is very bullish.  
 
 
In this first Point and Figure chart of VRTX, below, we used daily price data, which is projecting a potential upside price target in the $248 area. Not all that far above current levels.  
 
In this second Point and Figure chart of VRTX, below, we used weekly close-only prices. Here, the chart measures to a $271 price target. 
 
 
 
 
Bottom-line strategy: With a price target in the $270s and a risk point just below nearby support and the 50-day moving average line around $224, traders could go long VRTX.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Healthcare | Pharmaceuticals | Mad Money

More from Stocks

Get the Facts, Not the Hype, Then Trade

Paul Price
Jun 28, 2022 7:00 AM EDT

Rather than waste time trying to predict when, or if, a recession is on the way, why not simply buy shares that appear quite undervalued? Here are two to start with.

What's the 'Pain Trade' Now?

Helene Meisler
Jun 28, 2022 6:00 AM EDT

Is it more rallying to suck more people in? Or is it a rollover that will spit out those 'Sentiment Tourists'? Let's take a look.

Don't Shout 'V' for Victory, Yet

James "Rev Shark" DePorre
Jun 27, 2022 4:22 PM EDT

Even after last week's move higher and Monday's narrow range of movement, we can say it's going to be difficult to produce a 'V'-shaped setup like we had at the pandemic low in 2020.

Let's See If Vertex Pharmaceuticals Can Push Higher on the Charts

Bruce Kamich
Jun 27, 2022 3:03 PM EDT

Here's what traders should do.

LyondellBasell Could Hold Temporarily Before Renewed Declines

Bruce Kamich
Jun 27, 2022 2:22 PM EDT

Let's take a look.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • 12:10 AM EDT PAUL PRICE

    More Insider Buying in American Woodmark (AMWD)

    American Woodmark , which I've discussed here fr...
  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login